Why the study?
Enoxaparin dosing recommendations for morbidly obese patients are lacking, prompting investigation into whether a reduced-dose strategy is more effective than standard dosing at achieving goal anti-Xa levels.
Does reduced dose enoxaparin (0.8 mg/kg) improve achievement of goal anti-Xa levels compared to standard dose (1 mg/kg) in acutely ill morbidly obese patients?
Does reduced dose enoxaparin (0.8 mg/kg) improve achievement of goal anti-Xa levels compared to standard dose (1 mg/kg) in acutely ill morbidly obese patients?
Reduced dose enoxaparin (0.8 mg/kg) achieved goal anti-Xa levels in 89% of morbidly obese patients, suggesting it is a reasonable dosing strategy.
Answers are grounded in this paper and cite their sources.
May support reduced enoxaparin dosing in morbidly obese patients; leaves open need for randomized confirmation of outcomes.
BACKGROUND: Enoxaparin dosing recommendations for morbidly obese patients are lacking. Retrospective and observational studies reported goal anti-Xa levels with a median dose of 0.8 mg/kg using total body weight. Further studies are needed to determine if a more conservative dosing strategy is warranted. OBJECTIVE: To determine if reduced dose enoxaparin was more effective than standard dose at achieving goal anti-Xa levels in morbidly obese patients. METHODS: . Patients were randomized to standard (1 mg/kg) or reduced dose (0.8 mg/kg) enoxaparin every 12 hours. The primary outcome was the proportion of patients with an initial anti-Xa at goal (0.5-1.1 IU/mL). RESULTS: A total of 62 patients were enrolled and randomized to 1 mg/kg (n = 32) or 0.8 mg/kg (n = 30), and 54 patients completed the study. The study did not meet accrual for 80% power. Goal anti-Xa levels were achieved in a similar proportion for the reduced-dose (n = 25/28) and standard dose arms (n = 20/26; 89.3% vs 76.9%; P = 0.29). Overall, 9 patients required dose adjustments, of which 6 were in the 1-mg/kg arm, and all were above goal. No documented bleeding or thrombotic events were reported. CONCLUSIONS AND RELEVANCE: . Overall, 89% of patients had a goal anti-Xa when initiated on 0.8 mg/kg. Based on the results, reduced dose enoxaparin may be a reasonable dosing strategy in morbidly obese patients.
No takes yet. Share an insight, caveat, or question.
Curry et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: